Enanta Pharmaceuticals, Inc.
HealthcareNASDAQ:ENTA · NASDAQ Global Select
+$0.39 today
Vol 0.19M · Avg 0.17M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-126.5%
avg -24.4%
ROIC
-31.4%
avg -8.4%
ROA
-29.2%
avg -6.7%
Analysis
ROA is currently the strongest return metric at -29.2% versus its period average of -6.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Scott T. Rottinghaus | Chief Medical Officer | $863,706.00 | — | 52 | $28,667.00 | 0.12% |
Yat Sun Or | Chief Scientific Officer | $814,285.00 | — | 74 | $378,267.00 | 1.63% |
Jay R. Luly | President, Chief Executive Officer & Director | $742,273.00 | — | 70 | $878,026.00 | 3.78% |
Nathaniel S. Gardiner | Consultant | $672,675.00 | — | 72 | $8,377.00 | 0.04% |
Brendan Luu | Chief Business Officer | $622,856.00 | — | 51 | $41,634.00 | 0.18% |
Matthew Kowalsky | Chief Legal Officer & Corporate Secretary | $575,652.00 | — | 53 | $1,318.00 | <0.01% |
Tara Lynn Kieffer | Chief Product Strategy Officer | $496,852.00 | — | 48 | $37,182.00 | 0.16% |
Harry R. Trout | VP of Finance & Interim Principal Financial Officer | — | — | 57 | $878,026.00 | 3.78% |
Kathleen S. Capps | Executive Director of Accounting, Controller & Interim Principal Accounting Officer | — | — | 41 | $8,377.00 | 0.04% |
Jennifer Viera | Executive Director of Investor Relations & Corporate Communications | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
9
$183,166.60
Net Sentiment
$183,166.60
Net selling
Most Active
Capps Kathleen S.
2 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 9 sells worth $183,166.60 over the last 12 months. That adds up to net selling of $183,166.60. Capps Kathleen S. was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -20.4% | N/A1 analysts |
| Revenue | N/A | N/A | +56.8% | -2.9% (15yr)2 analysts |
| Net Income | N/A | N/A | +54.5% | N/A2 analysts |
| EBIT | N/A | N/A | +80.0% | N/A2 analysts |
Analysis
Recent growth has been strongest in EBIT at +80.0% over three years. Forward estimates point to Revenue at -2.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Assembly Biosciences, Inc.
NASDAQ:ASMB
$364.90M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$359.32M
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$352.45M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
$284.66M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$245.42M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$211.47M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.19M
Immuneering Corporation
NASDAQ:IMRX
$152.11M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$118.59M
Pyxis Oncology, Inc.
NASDAQ:PYXS
$111.51M
Who manages ENTA?
Enanta Pharmaceuticals, Inc. (ENTA) lists 10 active executives. The top listed executive is Scott T. Rottinghaus, Chief Medical Officer.
Are ENTA insiders buying or selling?
Recent insider activity shows net buying of $26.88M.
Explore More
Continue the stock analysis
Jump to another research area for this company.